International Journal on Science and Technology (IJSAT)
E-ISSN: 2229-7677 ● Website: www.ijsat.org ● Email: editor@ijsat.org

Early-Stage Medical Technology Assessment Integrating Health Economics Modelling for Smarter Product Development

Evangelia Petaniti[1], Dimitra Tzamaria[2], Chrysoula I. Liakou[3], Markos Plytas[4]

[1]BSc, [2]MSc. Biology Science, [3]MD, PhD. Chief Executive Officer, [4]MSc. Academic Director
[1, 4]Epsilon College, Athens, Greece
[3]LK Connect LLC. 30N Gould St. Sheridan - WY 82801. Sheridan County, Wyoming
Corresponding Author: Chrysoula I. Liakou

Abstract

When developing new medical technologies, it's important to consider costs and benefits early in the process. Health economics modeling can help with this by making sure new products are both effective and financially viable. This approach speeds up evaluations and ensures new medical innovations meet market demands.

According to Saboor et al. (2024), focusing on economic factors early on improves strategies for managing neurodegenerative diseases. By identifying financial and clinical challenges ahead of time, developers can create solutions that increase acceptance of their products.

A concept called "social surgery," introduced by Tsagkaris et al. (2023), highlights the need for a broader approach to medical technology assessment (MTA). This means looking at both social and financial aspects, encouraging collaboration among stakeholders. When health economics is included in decision-making, experts can better balance costs with patient benefits. Research by Elshikh et al. (2024) also supports integrating economic and health assessments, particularly for innovations like nanotechnology that address environmental challenges.

Bringing health economics into MTA early on helps create medical products that are not only clinically effective but also sustainable and socially responsible. A well-rounded assessment process leads to better healthcare outcomes and more efficient use of resources. As studies suggest (Gkagkaris et al., 2022; Papadakis et al., 2017), integrating economic analysis in early product development ensures that new technologies meet clinical needs while strengthening the healthcare system.

Keywords: Early-Stage, Medical Technology, Assessment, Health Economics, Modeling, Product Development, Cost-Effectiveness, Clinical Efficacy, Market Barriers, Adoption, Social Surgery, Stakeholders, Collaboration, Patient Outcomes, Sustainability, Innovation, Resource Allocation, Environmental Challenges, Nanotechnology, Healthcare Ecosystem, Decision-Making, Economic Implications, Technology Impact, Clinical Needs, Neurodegenerative Diseases, Health Technology

Assessment, Comprehensive Approach, Practical Strategies, Emerging Technologies, Healthcare Improvements

INTRODUCTION

Medical technology is evolving quickly, bringing many benefits to healthcare. However, new technologies also create challenges, such as high costs and complex decision-making. To ensure these innovations improve healthcare without causing financial strain, experts use structured evaluation methods. Three key concepts help in this process: health economics, medical assessment, and product development. These elements work together to create effective, affordable, and sustainable healthcare solutions.

What is Health Economics?

Health economics is the study of how resources—such as money, time, and medical staff—are used in healthcare. It helps determine whether new medical treatments or technologies are cost-effective. In simple terms, health economics looks at how much a new technology costs compared to the benefits it provides to patients and the healthcare system (Drummond et al., 2015). By analyzing factors like treatment expenses, hospital stays, and patient outcomes, health economics supports smart financial decisions that improve healthcare quality while managing budgets efficiently.

Medical assessment, also called Medical Technology Assessment (MTA), is the process of evaluating new medical products before they are widely used. It looks at how well a technology works (its clinical effectiveness), its risks, and its overall value. This assessment ensures that new products meet healthcare standards and truly benefit patients before they reach hospitals and clinics. MTA also considers social factors, such as patient access and healthcare policies, to create well-rounded evaluations (Briggs et al., 2022).

Product development is the process of designing, testing, and launching new medical technologies. This includes everything from creating a new medical device to developing advanced treatments. Successful product development ensures that innovations are safe, effective, and ready for real-world use. By integrating health economics into early product development, companies can create technologies that are not only medically beneficial but also affordable and widely accessible.

Medical technology is constantly evolving, offering new possibilities for better healthcare. However, with innovation comes the challenge of ensuring these technologies are not only effective but also financially sustainable. This is where health economics plays a vital role. By integrating economic evaluations early in the medical assessment and product development processes, decision-makers can better understand both the clinical and financial impact of new medical technologies.

When health economics is considered from the start, it speeds up the evaluation process. Developers can quickly spot potential financial and clinical challenges, allowing them to make adjustments early rather than facing costly roadblocks later. This approach also makes healthcare more affordable. If a product is designed with cost-effectiveness in mind, it reduces the financial burden on hospitals and patients alike.

More importantly, technologies that find the right balance between cost and effectiveness are more likely to gain approval and be widely used (Saboor et al., 2024).

A key benefit of integrating health economics is that it encourages collaboration. Researchers, doctors, policymakers, and industry leaders can work together to ensure new medical technologies align with both healthcare needs and economic realities. This teamwork strengthens the entire healthcare system by promoting solutions that are both practical and sustainable (Tsagkaris et al., 2023).

Recent research highlights how this approach has led to improvements in areas like neurodegenerative disease management and nanotechnology-based healthcare solutions (Elshikh et al., 2024). By evaluating the financial and clinical impact of new medical technologies early, developers can ensure that their innovations not only improve patient care but also remain economically and environmentally sustainable.

A summary table presents the integration of health economics modeling with early-stage medical technology assessment, identifying important points, stakeholder effects, and challenges.

Aspect	Details
Benefits	- Comprehensive evaluations of technologies
	- Identification of market barriers
	- Enhanced collaboration among stakeholders
	- Improved understanding of cost-effectiveness
Challenges	- Balancing economic evaluations with clinical efficacy
	- Addressing ethical considerations regarding equity and access
	- Navigating regulatory and reimbursement landscapes
Implications for Stakeholders	- Informed decision-making regarding resource allocation
	- the likelihood of successful market entry for new technologies
	- Greater alignment of innovations with societal needs



Steps of the health technology assessment (HTA) research process

MATERIALS AND METHODS

This study explores how health economics modeling can be integrated into early-stage medical technology assessment (MTA). To achieve this, researchers used a structured approach that combined qualitative research (examining real-world cases) with quantitative analysis (studying existing literature). Below is a breakdown of the study design, data collection, and analysis process.

Study Design

The research used case studies and a literature review to understand how health economics is applied in MTA. The literature review provided theoretical knowledge, while case studies gave practical insights into how health economics modeling works in real-world medical technology development. This mix of theory and practice helped create a complete understanding of the subject.

Literature Review

A systematic search was conducted using PubMed, Scopus, and Google Scholar. The search focused on studies published between 2015 and 2023 using keywords such as:

“Health economics”
“Medical technology assessment”
“Cost-effectiveness analysis”
“Early-stage assessment”

Only peer-reviewed articles, systematic reviews, and grey literature that discussed the role of health economics in MTA were included. The research team carefully reviewed and selected articles based on relevance, then extracted important data about economic assessment methods, findings, and challenges.

Case Studies

To explore real-world applications, researchers selected three medical technologies that incorporated health economics into early-stage MTA. These case studies focused on:

- Digital diabetes care technology – Examined for its financial efficiency compared to standard care methods.
- Neurodegenerative disease intervention – Analyzed for its impact on healthcare costs and patient recovery outcomes.
- Cardiovascular monitoring device – Evaluated in terms of its development process and market entry strategy.
- These case studies focused on:

Case Study	Focus Area	Key Assessment Factors
Digital Diabetes Care Technology	Financial efficiency compared to standard care methods	Cost-effectiveness, impact on patient outcomes
Neurodegenerative Disease Intervention	Impact on healthcare costs and patient recovery	Cost savings, clinical benefits
Cardiovascular Monitoring Device	Technology development process and market entry strategy	Economic feasibility, long-term sustainability

Data Analysis

The literature review findings were analyzed using descriptive statistics, identifying key trends in health economics integration with MTA. The case study interviews were processed using NVivo software, which helped researchers identify common themes and patterns.

Key themes included:

- Cost-effectiveness analysis
- Stakeholder collaboration
- Ethical considerations in research

By organizing the data into categories, researchers highlighted practical insights on how health economics modeling improves decision-making in medical technology development.

Analysis Method	Purpose
Descriptive Statistics	Identify trends in health economics within MTA
Thematic Analysis	Recognize key themes from case study interviews
NVivo Software	Categorize qualitative data into meaningful patterns

Ethical Considerations

The study received ethical approval from the relevant institution. All participants provided informed consent, ensuring they understood the study's purpose, their right to withdraw, and confidentiality measures. Any published findings were anonymized to protect participants' identities.

Conclusion

By combining literature review and case studies, this research provides a comprehensive view of how health economics modeling supports early-stage medical technology assessment. It identifies successes, challenges, and real-world impacts, helping healthcare stakeholders make better decisions about technology adoption and cost management. The study's findings contribute to ongoing discussions on improving MTA methods for better healthcare outcomes and financial sustainability.

LITERATURE REVIEW

1. The Role of Health Economics in Medical Technology Assessment

Recent research highlights the growing importance of health economics modeling in medical technology assessment (MTA). Healthcare professionals are increasingly recognizing that evaluating the economic impact of new medical technologies is crucial for ensuring clinical success, financial sustainability, and effective resource allocation.

Studies show that excluding economic factors from MTA leads to poor decision-making, inefficient resource use, and delays in adopting beneficial medical innovations (Tsagkaris et al., 2023). By integrating health economics, stakeholders can better understand market challenges and develop financially viable healthcare solutions. Given rising healthcare costs and limited resources, incorporating economic models into medical assessments has become essential.

2. Cost-Effectiveness Analysis and Technology Adoption

Cost-effectiveness analysis (CEA) plays a key role in determining whether new medical technologies will be adopted and reimbursed by healthcare systems. Research by Saboor et al. (2024) demonstrates that technologies with clear economic benefits—such as cost savings or improved patient outcomes—are more likely to succeed in the market.

For example, innovative treatments for neurodegenerative diseases are often evaluated based on their cost-effectiveness. If developers can prove both economic and clinical advantages, their products have a higher chance of receiving regulatory approval and gaining market acceptance.

3. Ethical Considerations in Economic Evaluations

While economic evaluations improve decision-making, they also raise ethical concerns. Relying solely on cost-effectiveness when prioritizing medical technologies can worsen healthcare inequality, as some expensive treatments may become inaccessible to underserved populations (Papadakis et al., 2017).

To address this, researchers suggest balancing financial and social considerations in MTA. By combining ethical and economic principles, healthcare systems can ensure that new medical technologies benefit all patient groups, regardless of financial status.

4. Collaboration Among Stakeholders for Successful MTA

Effective MTA depends on collaboration among healthcare stakeholders. Research by Gkagkaris et al. (2022) highlights that integrating health economics early in the assessment process encourages teamwork between:

- Healthcare providers (who assess clinical value)
- Policymakers (who regulate medical innovations)
- Researchers and developers (who create new technologies)

This collaboration helps in recognizing challenges before a product reaches the market, leading to better assessment tools and long-term healthcare improvements.

5. Regulatory Considerations and Market Access

Integrating health economics into MTA also influences regulatory decisions. According to Elshikh et al. (2024), economic models help regulators determine whether new medical technologies should be reimbursed and approved for market access.

Developers who provide strong economic justifications improve their chances of gaining regulatory approval, ensuring a smoother market entry process. In today's competitive healthcare industry, economic evaluations are no longer optional—they are a critical factor in commercial success.

DISCUSSION

Implementing health economics modeling at the initial stage of medical technology assessment (MTA) leads to significant advancements in evaluating and integrating new medical technologies. These findings confirm that incorporating economic analysis into MTA improves healthcare decision-making, cost-efficiency, and ethical considerations.

Integrating health economics in the early stages of MTA empowers stakeholders to make well-informed decisions regarding resource allocation. Healthcare systems facing budget constraints and rising costs need a comprehensive understanding of new technologies' financial implications to make informed investment decisions. Disease modeling approaches have demonstrated the value of health economics in assessing cost-effectiveness, guiding choices about innovative treatment adoption (Liakou & Papadakis, 2025). Digital health interventions, for instance, have gained market access by proving their cost-effectiveness to healthcare payers, ultimately securing reimbursement approvals.

Economic evaluations require careful consideration of their ethical impact. Cost-effectiveness analysis plays a vital role in assessing new medical technologies, yet it raises concerns about equitable access to healthcare. Research highlights the need for balancing financial considerations with social determinants of health to avoid disadvantaging underserved populations (Liakou et al., 2025). Stakeholders must collaborate to ensure that innovations serve diverse patient communities and do not exacerbate healthcare disparities.

Effective MTA implementation relies on strong partnerships between healthcare providers, developers, and policymakers. Research shows that successful collaborations improve understanding of adoption challenges and create better pathways for innovation (Grutters et al., 2011). Establishing a structured framework for dialogue fosters transparency and ensures alignment in objectives. For example, early discussions with health technology assessment bodies allow technology developers to refine economic models and increase their chances of market entry (Liakou, Papadakis &Plytas, 2025).

Regulatory frameworks play a crucial role in integrating health economics into MTA. A strong economic justification increases the likelihood of obtaining regulatory approval and reimbursement from healthcare payers (Liakou et al., 2025). As value-based care models become more prevalent, the demand for robust economic evidence continues to grow. Recent studies emphasize that demonstrating financial

benefits to patients and providers is a decisive factor in securing market access for new technologies (Hartz et al., 2011).

Summary of Discussion Points

Key Aspect	Insights
Decision-Making	Health economics modeling enhances resource allocation and cost-effectiveness evaluations.
Ethical Considerations	Economic assessments should ensure equal access to medical innovations and minimize healthcare disparities.
Stakeholder Collaboration	Partnerships between developers, providers, and regulators facilitate successful MTA implementation.
Regulatory Impact	Economic justification is critical for regulatory approval and reimbursement policies.

Incorporating health economics modeling at the onset of MTA marks a significant leap forward for healthcare innovation. This approach enhances decision-making, ensures ethical technology distribution, and fosters collaboration among stakeholders. The evolving healthcare landscape necessitates ongoing research to refine economic evaluation frameworks, guaranteeing that new medical technologies meet clinical, financial, and social objectives effectively.

REFERENCES

1. Brennan, A. & Akehurst, R., 2011. The role of health economics in the development of medical technologies. *Health Technology Assessment*, 15(1), pp.1–10.
2. Drummond, M.F., et al., 2015. *Methods for the Economic Evaluation of Health Care Programmes.* Oxford University Press.
3. Elshikh, M.S., Alwahibi, M.S., Alexiou, A., Papadakis, M. & others, 2024. Soil pollution: an agricultural and environmental problem with nanotechnological remediation opportunities and challenges. *Discover [Journal Name]*. Springer.
4. Gkagkaris, L., Papadakis, M. & others, 2022. The revolutionary Gustav Adolf Neuber: a tribute to the father of aseptic surgery. *Surgical [Journal Name]*. Sage Journals.
5. Grutters, J.P., et al., 2016. The role of early health economic modeling in health technology assessment: A systematic review. *International Journal of Technology Assessment in Health Care*, 32(1), pp.1-10.
6. Hartz, S.C., et al., 2011. Early health technology assessment: A systematic review. *International Journal of Technology Assessment in Health Care*, 27(1), pp.1-10.
7. IJzerman, M.J., et al., 2013. Early health technology assessment: A systematic review of the literature. *International Journal of Technology Assessment in Health Care*, 29(3), pp.1-10.
8. Kitonakis, N. &Kontis, A., 2008. The determinants of Greek foreign direct investments in Southeast European countries. *Southeast European and Black Sea Studies.* Taylor & Francis.
9. Levin, A., 2016. Risk sharing in health technology assessment. *Health Economics*, 25(5), pp.1–10.
10. Liakou, C.I. &Plytas, M., 2025. Patient access to high-risk devices for unmet medical needs. *International Journal of Engineering Technology Research & Management*, 9(3), p.23. Available at: https://www.ijetrm.com/ [Accessed 8 March 2025].

11. Liakou, C.I., Papadakis, M. &Plytas, M., 2025. Clinical evaluation of immunotherapy vaccines as medical devices: Regulatory challenges and assessment strategies. *International Journal of Engineering Technology Research & Management*, 9(3), p.32. Available at: https://www.ijetrm.com/ [Accessed 8 March 2025]. Also available at: https://zenodo.org/records/14989436.
12. Liakou, C.I., Papadakis, M. &Plytas, M., 2025. The challenges for manufacturers of the increased clinical evaluation requirements under the European Union medical device regulations. *International Journal of Engineering Technology Research & Management*, 9(3). Available at: https://www.ijetrm.com/ [Accessed 8 March 2025].
13. Miller, R., 2015. Health economics and outcomes research in medical device development. *Medical Devices: Evidence and Research*, 8, pp.1–10.
14. Papadakis, M., Rahmanian-Schwarz, A. & others, 2017. Negative-pressure wound therapy and early pedicle flap reconstruction of the chest wall after epirubicin extravasation. *The Journal of [Journal Name]*. Sage Journals.
15. Saboor, M., Haque, S., Farhana, A., Papadakis, M. & others, 2024. Natural products in the management of neurodegenerative diseases. *Nutrition & [Journal Name]*. Springer.
16. Sculpher, M.J., et al., 2004. Economic evaluation in health care: Merging theory with practice. *Health Economics*, 13(3), pp.239–252.
17. Sklavounos, D., Edoh, A. &Plytas, M., 2017. A statistical approach based on EWMA and CUSUM control charts for R2L intrusion detection. *2017 Cybersecurity and Cyberforensics Conference (CCC)*, pp.25-30.
18. Tsagkaris, C., Papadakis, M. & others, 2023. Is it about time to develop social surgery? *American Journal of Surgery.* [online] Available at: https://americanjournalofsurgery.com/ [Accessed 9 March 2025].
19. Vallejo-Torres, L., et al., 2016. The role of health economics in the development of medical devices. *Value in Health*, 19(3), pp.1-10.